Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded down 5.3% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $322.69 and last traded at $324.57. 1,403,610 shares traded hands during mid-day trading, an increase of 32% from the average session volume of 1,066,957 shares. The stock had previously closed at $342.67.

Specifically, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 10.80% of the company’s stock.

A number of research analysts recently issued reports on the stock. Barclays cut shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $450.00 to $395.00 in a research report on Friday, October 20th. Jefferies Group reissued a “hold” rating and set a $421.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, February 2nd. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the company an “equal weight” rating in a research report on Friday, February 9th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Finally, Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $463.19.

The firm has a market capitalization of $34,890.00, a P/E ratio of 31.45, a price-to-earnings-growth ratio of 1.27 and a beta of 1.47. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $1.05. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. Regeneron Pharmaceuticals’s revenue was up 28.9% compared to the same quarter last year. During the same period last year, the business earned $3.04 EPS. equities research analysts anticipate that Regeneron Pharmaceuticals Inc will post 14.13 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in REGN. Harding Loevner LP grew its stake in shares of Regeneron Pharmaceuticals by 589.2% in the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after acquiring an additional 3,131,966 shares during the period. Renaissance Technologies LLC grew its stake in shares of Regeneron Pharmaceuticals by 516.8% in the fourth quarter. Renaissance Technologies LLC now owns 579,562 shares of the biopharmaceutical company’s stock worth $217,892,000 after acquiring an additional 485,600 shares during the period. Old Mutual Global Investors UK Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 500,446.2% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock worth $145,472,000 after acquiring an additional 325,290 shares during the period. UBS Asset Management Americas Inc. grew its stake in shares of Regeneron Pharmaceuticals by 93.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 553,501 shares of the biopharmaceutical company’s stock worth $208,094,000 after acquiring an additional 267,442 shares during the period. Finally, Bank of Montreal Can grew its stake in shares of Regeneron Pharmaceuticals by 342.4% in the fourth quarter. Bank of Montreal Can now owns 188,828 shares of the biopharmaceutical company’s stock worth $70,991,000 after acquiring an additional 146,147 shares during the period. Hedge funds and other institutional investors own 65.89% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/02/14/regeneron-pharmaceuticals-regn-shares-down-5-3-after-insider-selling.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.